The patent application was granted by the UK Intellectual Property Office during the summer holidays, and the certificate of grant has been issued. 

CEO of Immuvera Therapeutics, Jørund Sollid

" Securing this patent is an important step in delivering on our mission: developing novel immunotherapies for companion animals and translating those insights to human medicine. A robust intellectual property portfolio lays the foundation for longterm company value and investor confidence, helping us to attract partnerships and funding needed to advance our programs. As we continue to innovate in comparative oncology and immunotherapy, we will work diligently to protect our discoveries and build value for our shareholders and the patients, both canine and human that we aim to serve. The grant is a significant milestone for our company and underscores the innovative work being done by our scientific team”.

For any questions regarding this patent or our intellectual property strategy, please contact us via the details listed on our website. We thank our patent attorneys for their diligent work and look forward to sharing more updates as our IP portfolio grows.